Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

PWRM, CLWR, CMCSA, S, VVUS - Power3 Medical Products, Clearwire, Comcast, Sprint, Vivus

|Includes: Sprint Corporation (S)


Stock-PR Reporting



FREE Daily Stock Alerts From






Clearwire Corporation (Nasdaq:CLWR)

CLWR, Comcast (NASDAQ:CMCSA) and Sprint (NYSE:S) announced plans to launch their respective 4G mobile internet services in the high-tech mecca of San Francisco later this year. Each of the companies will offer 4G services under their own 4G brand. Clearwire, Comcast and Sprint will each launch commercial 4G service in the San Francisco Bay Area in late December, with official launch events and retail store openings to follow across the region. Consumers and businesses should expect to see additional network expansions throughout the city, and a wide range of independent marketing and advertising initiatives.

Clearwire Corporation, through its subsidiaries, builds and operates mobile broadband networks that provide high-speed residential and mobile Internet access services and residential voice services in communities in the United States. It offers wireless broadband and mobile broadband services, as well as voice over Internet protocol telephony services for homes and offices. The company also leases residential modems, as well as sells modems and personal computer cards.

Comcast Corporation, together with its subsidiaries, provides consumer entertainment, information, and communication products and services to the residential and commercial customers in the United States.

Sprint Nextel Corporation offers wireless and wireline communications products and services to consumers, businesses, and government users in the United States, Puerto Rico, and the U.S. Virgin Islands. Its Wireless segment provides wireless mobile voice and data transmission services on networks that utilize CDMA and iDEN technologies, as well as offers fourth generation wireless services.


VIVUS Inc. (Nasdaq:VVUS)

VVUS announced that data on QNEXA, an investigational drug candidate, will be featured in two oral presentations at the 1st International Diabetes and Obesity Forum, being held October 21-23, 2010 in Athens, Greece. Both presentations will be made by Dr. Louis J. Aronne, MD, today, Saturday, October 23, 2010 from 2:00 to 3:30 pm in the Santorini Hall of the Hilton Athens.

VIVUS, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products for underserved markets in the United States. It offers MUSE, a minimally invasive therapy for erectile dysfunction. The company’s investigational product pipeline includes Qnexa that has completed Phase 3 clinical trials for obesity, and Phase 2 clinical trials for diabetes and obstructive sleep apnea; Avanafil, which is in phase 3 clinical trials to treat erectile dysfunction; and Luramist, which has completed phase 2 clinical trials for the treatment of hypoactive sexual desire disorder in women.


  Power3 Medical Products, Inc. (OTC:PWRM)

PWRM  recently delivered four poster presentations at the 2010 ICAD. These presentations discussed PWRM’s diagnostic test, NuroPro, and focused on PWRM’s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.

PWRM has filed several patent applications that are currently pending for its NuroPro technology. PWRM also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, PWRM has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China. PWRM  has also published 6 articles on NuroPro in peer-reviewed scientific journals. PWRM intends to publish these latest findings as well.

PWRM, a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. PWRM’s products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease. PWRM ’s products analyze proteins and their mutations to assess an individual’s risk for developing disease later in life or a patient’s likelihood of responding to a particular drug; assess a patient’s risk of disease progression and disease recurrence; and measure a patient’s exposure to drug therapy. PWRM was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. PWRM was founded in 1992 and is based in The Woodlands, Texas.

To learn more about PWRM visit:





Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).

Sign Up For Free Stock Alerts At


Be Sure To Visit


The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.